生物活性 | |||
---|---|---|---|
描述 | Praziquantel (PZQ) is the drug of choice for treatment of all human schistosomes. There were marked cure and egg reduction rates, together with mild and short lived side effects of PZQ for treatment of S. haematobium[3]. Praziquantel 40 mg/kg was effective at reducing infection intensity in all Schistosoma species without differences between preschool- and school-aged children[4]. The relative bioavailability of praziquantel injection was 402.5% in contrast to praziquantel tablet. The praziquantel injection has pharmacokinetic characteristics of rapid absorption, high bioavailability and extensive distribution, and the clinical recommended dosage of praziquantel injection is 10 mg/kg[5]. Praziquantel given as an in situ slow-release formulation by subcutaneous injection resulted in concentrations of the active principle in beagle dogs, which should be capable of resisting new Echinococcus infections for at least 6 months[6]. |
临床研究 | |||||
---|---|---|---|---|---|
NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
NCT02366884 | Neoplasms | Phase 2 | Enrolling by invitation | December 31, 2020 | United States, Maryland ... 展开 >> Atavistic Chemotherapy Clinical Trial Bethesda, Maryland, United States, 20814 Mexico Dr. Frank Arguello Cancer Clinic San Jose del Cabo, Baja California Sur, Mexico Instituto de Ciencia y Medicina Genomica Torreon, Coahuila, Mexico 收起 << |
NCT03041766 | Schistosomiasis | Phase 2 | Completed | - | Senegal ... 展开 >> Biomedical Research Center EPLS Saint Louis, Senegal, BP226 收起 << |
NCT00276224 | Schistosomiasis ... 展开 >> Helminthiases Anaemia 收起 << | Not Applicable | Completed | - | Zambia ... 展开 >> Kenani and Chandwe School Kenani, Nchelenge district, Zambia 收起 << |
实验方案 | |||
---|---|---|---|
1mg | 5mg | 10mg | |
1 mM 5 mM 10 mM |
3.20mL 0.64mL 0.32mL |
16.00mL 3.20mL 1.60mL |
32.01mL 6.40mL 3.20mL |
参考文献 |
---|